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Association of the resolvin 
precursor 17-HDHA, but not D- or 
E- series resolvins, with heat pain 
sensitivity and osteoarthritis pain in 
humans
Ana M. Valdes1,2,3, Srinivasarao Ravipati4,6, Cristina Menni1, Abhishek Abhishek2, Sarah 
Metrustry1, Juliette Harris1, Ayrun Nessa1, Frances M. K. Williams1, Tim D. Spector1, Michael 
Doherty2, Victoria Chapman3,5,6 & David A. Barrett  4
Resolvins are omega-3 fatty acid derived potent bioactive lipids that resolve inflammation and 
modulate transient receptor potential channels. Exogenous administration of the resolvin precursor 
17-HDHA shows a strong analgesic effect in animal models of osteoarthritis and acute inflammatory 
pain, but has not been studied in humans. Our aim was to assess the role of 17-HDHA and resolvins in 
heat pain sensitivity and in osteoarthritis pain in humans. Resolvins D1, D2, D3, D5, E1 and 17-HDHA, 
were measured by liquid chromatography-mass spectrometry and tested for association with heat pain 
thresholds in 250 healthy volunteers who had undergone quantitative sensory testing. Resolvins D1, D2 
and 17-HDHA were then tested in 62 individuals affected with knee osteoarthritis and 52 age matched 
controls and tested for association with knee pain. Circulating levels of docosahexaenoic acid (DHA) 
were also measured. Levels of 17-HDHA, but not those of the other 5 resolvins tested, were associated 
with increased heat pain thresholds (beta = 0.075; 95% CI 0.024, 0.126; p < 0.0046). 17-HDHA was 
associated with lower pain scores in OA patients (beta −0.41; 95% CI-0.69, −0.12; p < 0.005; adjusted 
for covariates) but not with radiographic osteoarthritis. The associations of 17-HDHA with heat pain 
sensitivity and osteoarthritis pain were independent of DHA levels.
Osteoarthritis (OA) is the fastest growing cause of chronic pain worldwide and is the commonest form of arthritis1. 
Pain is the predominant symptom of OA, which limits movement and causes disability2. It has long been recog-
nised that the amount of pain people with OA experience is variable and only weakly correlated to the extent of 
joint damage, but the molecular basis underlying variation in OA pain is poorly understood2. It is well established 
pro-inflammatory agents are released into the joint and that synovitis is highly correlated to OA pain3, various 
cytokines and pro-inflammatory mediators are released in damaged tissue and induce a cascade of events that 
lead to peripheral sensitization4. These mediators accumulate in the joint as OA progresses4 and act to reduce 
threshold of joint nociceptors.
Chronic localised inflammatory pain is a feature of several chronic diseases5. The role of specialised 
pro-resolvin molecules in curtailing inflammatory responses has been demonstrated in cell systems and in vivo, 
with a fundamental role in the maintenance of tissue homeostasis6. The best characterised of these resolution 
molecules are the resolvins, which are oxygenated metabolites (or oxylipins) of omega-3 fatty acids7. The omega-3 
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fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are the precursors of D and E-series 
resolvins, respectively6 (Fig. 1). Resolvins suppress cytokine production and “resolve” the destructive inflamma-
tion7 by regulating leukocyte trafficking and clearance of inflammatory mediators (e.g. cytokines, prostaglandins 
and leukotrienes, growth factors and reactive oxygen species). D- and E-series resolvins inhibit several transient 
receptor potential (TRP) channels in vitro5, 8 which are essential to cutaneous thermal and pain sensation9, 10. 
Thus, in addition to their effect on inflammatory mediators, these compounds may play a direct role in nocice-
ption and specifically on thermal pain. Resolvins are also able to modulate N-Methyl-D-Aspartic acid (NMDA) 
receptors11 (Fig. 1). Phosphorylation of these receptors has been associated with hyperalgesia, neuropathic pain, 
and reduced functionality of opioid receptors12.
Exogenous administration of resolvin E1 (RvE1) and resolvin D1 (RvD1) inhibits pain behaviour in animal 
models of acute inflammatory pain8 and in a model of chronic adjuvant-induced arthritis13.
RvD1 reduces mechanical allodynia and phosphorylation of NMDA receptors along with decreased cytokine 
expression in an animal model of chronic pancreatitis11. Moreover, RvD1 has been shown to significantly attenu-
ate arthritis severity and inflammation in a murine model of inflammatory arthritis but these protective actions 
are abolished in RvD1 receptor-deficient mice14.
Resolvins are rapidly degraded in vivo resulting in a short biological half-life, but this limitation can be over-
come by administration of precursors of the active molecules13. 17-HDHA is a metabolite of the omega-3 fatty 
acid docosahexaenoic acid (DHA), and a precursor of D-series resolvins. Inhibitory effects of exogenous omega-3 
fatty acids on pain and inflammation is evident in rheumatoid arthritis15, however a randomised clinical trial of 
high vs low dose omega-3 fatty acids failed to show an advantage of high omega-3 administration16.
Exogenous 17-HDHA halted progression of pain behaviour in a surgical model of OA pain17. However, 
17-HDHA did not alter the extent of joint pathology, pointing to potential direct effects on sensory nerves or in 
the central nervous system and suggesting the therapeutic potential of this new class of analgesics for the treat-
ment of OA pain. Thus, measurement of 17-HDHA may be useful in pinpointing the potential mechanisms of 
action of omega-3 on pain, which may reflect the effect of various D-series resolvins.
The potential role of resolvins and their metabolic precursors in human pain has yet to be explored, partly due 
to the lack of analytical methods for analysis of these lipids in biological tissues. Recent availability of authentic 
chemical standards for the resolvins and precursors has allowed the development of highly sensitive and specific 
liquid chromatography tandem mass spectrometry methods (LC-MS/MS) for their quantitative analysis18. The 
aim of our study was to assess the role of 17-HDHA and resolvins in pain sensitivity, both in acute heat pain 
and in OA pain in humans. To address this aim, we have firstly investigated if the D-series resolvin precursor 
17-HDHA is associated with thermal pain sensitivity per se in human volunteers, and whether any association 
with heat pain sensitivity can be explained by the levels of D- or E- series resolvins. Whether possible associ-
ations between 17-HDHA and pain sensitivity were reflective of omega-3 dietary intake was also established. 
Given the known role of inflammatory mediators in OA pain4 and potential link of pain responses to inflamma-
tion we also included in our model two omega-6 lipids, the prostaglandin precursor arachidonic acid (AA) and 
Figure 1. Relationship between the omega-3 lipids measured in this study and other omega 3-fatty acid derived 
oxylipins. The assays did not distinguish chirality therefore compounds measure can be either the 17-S or 
17-R enantiomers (e.g. 17-S-HDHA or 17-R-HDHA). Abbreviations: HEPE = Hydroxyeicosapentaenoic acid; 
RvE1 = resovlin E1; RvD(x) = resolvin Dx; PD1 = protectin D1; MaR1 = maresin 1; EPA = Eicosapentaenoic 
acid;DHA Docosahexaenoic acid; COX-2 + ASA = cycloxygenase -2 and aspirin; HpDHA = hydroperoxy 
docosahexaenoic acid; HDHA = hydroxy docosahexaenoic acid; OxoDHA = oxodocosahexaenoic acid. 
TRP = transient potential receptor; NMDA = N-Methyl-D-Aspartic acid.
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the leukotriene B4 recently reported to be involved in peripheral sensitization19. We then asked if 17-HDHA or 
D-series resolvins were associated with knee pain intensity in individuals with knee OA, and whether any putative 
associations with OA pain are reflective of DHA serum levels. Finally, we assessed whether levels of 17-HDHA 
were associated with OA status comparing individuals affected with radiographic knee OA to OA free controls.
Subjects and Methods
Details on the study cohorts are included in the Supplementary section. All methods in this study were performed 
in accordance with relevant guidelines and regulations. Briefly:
Subjects. TwinsUK cohort. The TwinsUK registry contains twin volunteers recruited through national 
media campaigns and from other twin registers. The study was approved by the St Thomas’ Hospital research 
ethics committee, and all participants provided written informed consent. Participants be comparable to the 
age-matched general population singletons for a broad variety of medical and behavioural traits20. Unselected 
twins (n = 2500) had been invited to attend St Thomas’ Hospital where they completed questionnaires gathering 
demographic information, clinical history and current medications. Exclusions included volunteers who had 
consumed analgesic medication within 12 hours of the study visit, and those with likely impaired upper limb 
neurology, e.g. known neuropathy, previous stroke or chemotherapy. Subjects having common painful conditions 
such as OA were not excluded21. Participants underwent sensory testing individually as previously described21. 
The heat pain threshold (HPT) represents the temperature at which the sensation evoked by a thermal stimulus 
changes from feeling ‘hot’ to feeling ‘painful’ while the heat pain super threshold (HPST) records the temperature 
at which the sensation changes from “painful to unbearable”. Venous blood was taken after the pain threshold 
testing (see below) and serum was extracted and stored at −80C. A subset of 250 samples was transferred to the 
School of Pharmacy in Nottingham. Five resolvins, one resolvin precursor, plus arachidonic acid and leukotriene 
B4 were measured in these samples. (see below).
Osteoarthritis case-control cohort. 62 individuals affected with radiographic knee OA (defined as Kellgren 
Lawrence grade of 2 or higher)22 and 52 individuals with no radiographic nor clinical symptoms of OA were 
recruited from existing databases of previous OA studies at the University of Nottingham. Approval for recruit-
ment was obtained from the research ethics committees of Nottingham City Hospital and North Nottinghamshire. 
Bilateral knee radiographs of index knee or hip OA cases were obtained at two time points and scored for features 
of OA by a single observer using the Kellgren and Lawrence grade for the tibio-femoral and patella femoral com-
partments of each knee22. Individuals also donated a blood sample from which plasma was extracted and stored 
for further analysis, and underwent a pain assessment. Participants completed a detailed nurse administered 
questionnaire on their symptoms and quality of life. Pain assessment was performed with the Western Ontario 
and McMaster Universities Arthritis Index (WOMAC)23 was used to quantify knee pain. Plasma samples were 
transferred for lipidomic analyses were carried that determine plasma concentration levels of the resolvin pre-
cursor (17-HDHA) and resolvins D1 and D2, plus arachidonic acid (AA) and leukotriene B4 (LTB4). In addition, 
levels of DHA and total omega-3 in the plasma samples were measured using the methods described below.
Laboratory analyses. Oxylipin and resolvin analysis method. The LC-MS/MS method used for eicosanoid 
analysis in human serum samples was based on the method previously developed24, 25 adapted for the inclusion 
of resolvins and precursors as described in the Supplementary Section. All lipid measurements were quantitative 
and had precision values of better than ±15% and accuracies in the range 85–115% as determined from the anal-
ysis of calibration and QCs with each batch of samples.
Quantification was performed using fully extracted calibration standards for each of the analytes. Measured 
concentrations of 17-HDHA, Resolvin D2, Resolvin D1, Resolvin D3, Resolvin D5, Resolvin E1, AA, LTB4 were 
detectable in each sample and are corrected for sample volume where appropriately needed.
NMR Metabolomics. DHA and total omega 3 fatty acids were measured by Brainshake Ltd, Finland, (https://
www.brainshake.fi/) from fasting serum or plasma samples using 500 MHz and 600 MhH proton nuclear mag-
netic resonance spectroscopy as previously described26.
Statistical analysis. Concentrations of all resolvins, DHA and omega-3 fatty acids were log-transformed 
for analysis. The association between bioactive lipids and heat pain thresholds in TwinsUK was carried out using 
linear regressions using the log transformed HPT and HSPT as the outcome and adjusting for family relatedness, 
age and BMI. Additional models including circulating levels of DHA were also tested. Association between log 
transformed WOMAC pain scores and plasma resolvins and DHA were adjusted for age, sex, BMI and K/L grade 
or OA status. Analyses were performed using R version 3.0.1 (www.cran.org).
Results
The descriptive characteristics of the participants of both cohorts are summarized in Table 1. Plasma levels of 
17-HDHA and D-series resolvins (OA case control) were lower than serum levels (TwinsUK cohort). The rela-
tionship between the omega-3 compounds measured is shown in Fig. 1.
Association with heat pain thresholds. We first tested if there was an association between the omega-3 
derived bioactive lipids and heat pain sensitivity after adjustment for potential confounders. Of the lipids quan-
tified, only 17-HDHA was associated with both HPST and HPT. None of the other D-series resolvins, or resolvin 
E1, were associated with pain sensitivity in this cohort. DHA and total omega −3 levels were associated with 
HPST but not HPT (Table 2). Adjustment for circulating levels of DHA did not alter the association between 
17-HDHA and heat pain thresholds (HPT and HPST) (Table 2).
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Overall, DHA and omega-3 fatty acids were poorly associated with the various resolvins and this only achieved 
statistical significance for 17-HDHA and RvD2 (Supplementary Table 1). The pro-inflammatory mediator AA 
cohort TwinsUK
Nottingham 
controls
Nottingham 
knee OA
n 250 52 62
sex F 100% 57.9% 61.1%
age mean (SD) 67.42 (8.08) 67.78 (7.35) 67.96 (8.62)
BMI kg/m2 mean (SD) 26.55 (4.40) 28.24 (5.12) 31.11 (6.43)
HPT °C mean (SD) 46.26 (2.24)
HPST °C mean (SD) 47.46 (1.84)
K/L grade 0|1|2|3|4 NA 0.81|0.19| 0|0|0 0 | 0 | 0.11|0.42|0.47
WOMAC (0–20) pain 
score mean (SD) NA 2.17 (3.70) 6.93 (4.37)
Serum bioactive lipids mean (SD)
RvD1(pmol/mL) 0.042 (0.089) NA NA
RvD2 (pmol/mL) 2.78 (3.34) NA NA
17-HDHA (pmol/mL) 162.32 (277.47) NA NA
RvD3 (pmol/mL) 0.23 (0.53) NA NA
RvD5 (pmol/mL) 0.39 (1.39) NA NA
RvE1 (pmol/mL) 0.68 (2.32) NA NA
DHA (mmol/L) 0.14 (0.05) NA NA
total omega 3 (mmol/L) 0.43 (0.13) NA NA
AA (pmol/L) 5531.10 (1949.4) NA NA
LTB4 (pmol/mL) 79.44 (212.64) NA NA
Plasma bioactive lipids mean (SD)
RvD1(pmol/mL) NA 0.022 (0.026) 0.22 (0.029)
RvD2 (pmol/mL) NA 1.24 (1.90 0.74 (0.86)
17-HDHA (pmol/mL) NA 26.98 (18.56 25.40 (19.06)
DHA (mmol/L) NA 0.13 (0.02) 0.13 (0.02)
total omega 3 (mmol/L) NA 0.34 (0.08) 0.33 (0.07)
AA (pmol/L) 3012.6 (1553.6) 3133.38 (1335.5)
LTB4 (pmol/mL) 14.86 (24.87) 10.27 (10.93)
Table 1. Descriptive characteristics of study cohorts. BMI = body mass index; HPT = heat pain threshold; 
HPST = heat pain super thresold; WOMAC = Western Ontario & McMaster Universities Osteoarthritis Index; 
K/L grade = Kellgren- Lawrence radiographic grade. RvDx = resolvin Dx; DHA = docohexadecanoic acid; 
AA = arachidonic acid. LTB4 = leukotriene B4.
logHPT log HPST
beta 95% CI p-value beta 95% CI p-value
RvD1 −0.005 (−0.046, 0.036) 0.805 −0.046 (−0.120, 0.028) 0.231
RvD2 0.021 (−0.006, 0.048) 0.133 0.000 (−0.051, 0.051) 0.988
17-HDHA 0.035 (0.008, 0.062) 0.012 0.075 (0.024, 0.126) 0.0046
RvD3 −0.023 (−0.050, 0.004) 0.100 −0.032 (−0.083, 0.019) 0.231
RvD5 −0.017 (−0.046, 0.012) 0.242 −0.033 (−0.086, 0.020) 0.226
RvE1 0.003 (−0.026, 0.032) 0.834 −0.017 (−0.072, 0.038) 0.545
DHA 0.017 (−0.016, 0.050) 0.329 0.030 (0.003, 0.057) 0.031
Total omega3 0.017 (−0.016, 0.050) 0.323 0.028 (0.003, 0.053) 0.036
AA 0.0001 (−0.002, 0.003) 0.921 0.002 (−0.004, 0.007) 0.571
LTB4 0.001 (−0.003, 0.005) 0.558 −0.001 (−0.007, 0.005) 0.752
17-HDHA adj(1) 0.033 0.006 0.060 0.018 0.071 0.016 0.126 0.011
DHA adj(1) 0.014 −0.019 0.047 0.410 0.029 0.002 0.056 0.038
Table 2. Association between serum resolvins and omega-3 fatty acids and heat pain thresholds (HPT) and 
heat pain super threshold (HPST) in the TwinsUK cohort. Association is expressed as the regression coefficient 
(beta) and the corresponding 95% confidence intervals (95% CI). The outcomes tested were HPT and HPST 
in the log scale, resolvin measures were also log transformed and regressons are adjusted for age, BMI and 
relatedness. 1Model includes both DHA and 17-HDHA in addition to age, BMI and family relatedness. 
Nominally significant associations are highlighted in bold.
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was negatively correlated with RvD2, RvD5, RvE1 and LTB4. LTB4 on the other hand was positively correlated 
with all the resolvins measured, except RvD2. However, we found no association between AA and LTB4 levels and 
heat pain thresholds. (Table 2).
We also assessed the correlations between the various resolvin compounds with each other, and with age and 
BMI (Supplementary Table 1). Although some resolvins were strongly correlated with each other, 17-HDHA was 
only significantly (and modestly) correlated with RvD2. The resolvins had no association with BMI, and only a 
weak correlation with age (Supplementary Table 1).
The distribution of the serum 17-HDHA levels in TwinsUK divided by categories of heat pain thresholds and 
heat pain super thresholds in the natural scale are shown in Fig. 2(A and B). Adjusting for the levels of LTB4 and 
AA had no effect on the association between 17-HDHA and HPT and HPST. The association between 17-HDHA 
and logHPT after adjusting for LTB4 and AA was beta = 0.0035 (95% CI 0.0008–0.0063 P = 0.0124), for logHPST 
it was beta = 0.0032 (95%CI 0.0010–0.0055; P = 0.005).
Association of 17-HDHA with OA and OA pain. Since 17-HDHA was associated with pain sensitivity 
in humans, we hypothesized that this compound and not other D-series resolvins would be associated with OA 
pain. Herein we demonstrate that 17-HDHA, but not resolvin D1 nor D2, was associated with pain scores overall 
(Table 3). This was the case both in cases and controls adjusting for OA status and in OA cases only (unadjusted 
Figure 2. Distribution of serum (A and B) and plasma (C) 17-HDHA by categories of pain sensitivity and 
pain severity. HPT = heat pain threshold HPST = heat pain super threshold, WOMAC = Western Ontario and 
McMaster Universities Arthritis Index (0 = no knee pain, 20 = highest level of knee pain).
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for radiographic severity first and then adjusted for radiographic severity) (Table 3). Moreover, we found no 
association between levels of any of the three resolvins and OA case control status (Supplementary Table 2). The 
distribution of plasma levels of 17-DHDA in the natural scale in three WOMAC pain scores categories in OA 
patients and is shown graphically in Fig. 2C.
Taken together the heat pain sensitivity data and the OA pain data suggest that circulating 17-HDHA is a 
compound directly involved in pain. However, omega-3 fatty acids are known to have anti-inflammatory and 
anti-nociceptive effects and therefore this association of 17-HDHA may simply reflect the effect of omega-3 fatty 
acids. To explore whether this is the case, we tested the association of 17-HDHA with pain scores adjusting for 
levels of DHA and for omega-3. DHA was significantly associated with pain scores independently of 17-HDHA, 
but the association between 17-HDHA remains significant and unaltered when including DHA or omega-3 in the 
model and the DHA effect is close to nominal significance even including 17-HDHA (Table 3). These data suggest 
that there may be two separate effects on pain and that the effect of 17-HDHA is not the one commonly attributed 
to omega-3/DHA. (Table 3) Finally, we adjusted results for the circulating levels of two omega-6 derived lipids 
(AA and LTB4) and the association between 17-HDHA and OA pain remained similar (Table 3).
Discussion
In this study we show for the first time that 17-HDHA is associated with pain in humans, specifically with thermal 
pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic adminis-
tration of 17-hydroxy docosahexaenoic acid (17-HDHA also abbreviated as 17-HDoHE) completely reversed 
established pain behaviour in the monosodium iodoacetate model of OA pain, an effect which lasted for 6 hours, 
and was sustained following repeated administration17.
We report that the relationship with two measures of heat pain threshold in the general population and with 
pain severity in OA patients is specific for the resolvin precursor 17-HDHA, and not evident for other D-series 
resolvins. The association between 17-HDHA and the three pain measures tested was not attenuated by adjust-
ment for DHA, total omega-3, arachidonic acid or leukotriene B4 levels. An association between DHA and HPST 
and OA pain was seen, but not with HPT which remained statistically significant only in the case of HPST after 
adjustment for 17-HDHA. These results indicate that the relationship between 17-HDHA and pain levels is not 
reflective of levels of DHA, since both compounds have independent effects on pain. This is suggestive of two 
separate mechanisms are involved, consistent with in vitro reports of the various DHA derived oxylipins involved 
in pain In particular a DHA effect not related to levels of 17-HDHA could be explained by the action of maresin 
1 (MaR1) which was not measured in our study (see Fig. 1).
The correlation between levels of DHA and 17-HDHA seen was only modest, which suggests that the antino-
ciceptive effects of 17-HDHA are unlikely to be strongly modulated by omega-3 dietary supplementation, and 
may depend on the efficiency of the metabolic pathways (15-lipoxygenase for the 17-S isomers or COX-2 plus 
aspirin for the 17-R oxylipins) that convert DHA to 17-HDHA, and not to other metabolites None of the com-
pounds tested were associated with OA case-control status consistent with the observation that repeated treat-
ment with exogenous 17-HDHA does not alter joint pathology in a rat model of OA17. This is different from the 
situation seen in animal models of rheumatoid arthritis, where D-series resolvins are strongly associated with 
joint pathology14.
compound (log) beta 95% CI p-value
RvD1 0.022 −0.033 0.078 0.430
RvD2 0.029 −0.095 0.152 0.649
17-HDHA −0.406 −0.690 −0.123 0.005
total omega3 −0.375 −0.775 0.024 0.065
DHA −1.316 −2.532 −0.100 0.034
(DHA + 17-HDHA in same model)
17-HDHA −0.396 −0.686 −0.105 0.008
DHA −1.282 −2.582 0.018 0.053
(omega 3 + 17-HDHA in same model)
17-HDHA −0.401 −0.682 −0.121 0.005
Total omega3 −0.352 −0.779 0.074 0.106
17-HDHA adj for 
LTB4 −0.364 −0.678 −0.051 0.024
17-HDHA adj 
for AA −0.460 −0.779 −0.141 0.005
(OA + controls)
log17-HDHA −0.123 −0.234 −0.012 0.029
Table 3. Association between plasma resolvins, omega-3 fatty acids and OA pain in the Nottingham cohort. 
The outcome of all regressions is the log-transformed WOMAC pain score (+1). A higher WOMAC score 
indicates more main. Regressions were first run only in OA patients adjusting for age, sex, BMI and K/L grade. 
In selected models both 17-HDHA and DHA or total omega 3 were tested for association together, finally 
association between 17-HDHA and WOMAC scores was tested in the combined case-control group adjusting 
for OA status in addition to all other covariates.
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Further studies are needed to understand the mechanisms by which 17-HDHA mediates an analgesic effect. 
One possibility is that higher levels of 17-HDHA lead to higher levels of 17-HpDHA, which in turn can be epoxi-
dized into protectin D1 (Fig. 1). Although this mechanism could explain the human data it is harder to reconcile 
with the strong and long lasting analgesia produced by exogenous administration of 17-HDHA in rodent models 
of OA17. Another possibility is that the inhibitory effects of 17-HDHA are all due to RvD4 (not measured in our 
study but known to modulate receptors involved in nociception), or that 17-HDHA may be directly involved in 
modulating pain and pain sensitivity.
Transient receptor potential (TRP) family of ligand-gated ion channels, in particular TRPV1, have an estab-
lished role in thermal sensitivity9 and contributes to pain in OA (e.g. ref. 27). Previous studies have reported 
effects of the resolvins on TRP channels. In an in vitro dorsal root ganglia (sensory nerve) preparation RvD1 sup-
pressed the activity of various TRP channels (TRPA1, TRPV3 and TRPV4), but not TRPV1 and TRPV2 activity. 
TRPV1 activity was however inhibited by RvE15. D- and E-series resolvins also modulate NMDA receptors in ani-
mal models12 and reduce mechanical allodynia and pain behaviour in models of chronic pancreatitis11. However, 
in our human study neither RvD1 nor RvE1 are associated with thermal pain thresholds. To our knowledge the 
role of 17-HDHA on TRP channels has not been reported in the literature12, therefore it is feasible that 17-HDHA 
may have direct effects on TRP function. Additional mechanisms by which 17-HDHA may exert an effect on pain 
includes a metabolite of 17-HDHA, 17-oxoDHA which is an agonist at peroxisome proliferator activated recep-
tors (PPAR) alpha and gamma28. Interestingly, PPAR-alpha and gamma agonists have anti-nociceptive effects in 
a rat model of irritable bowel syndrome via a nitric-oxide mediated mechanism29.
Our study highlights for the first time the potential of 17-HDHA as a biomarker for pain and provides a plat-
form for a potential new approach to analgesia. Nevertheless, to separate 17-S and 17-R isomers of the various 
compounds would enable further mechanistic insight. For example, levels of RvD2 could be reflecting more 
activity via the 17-S (15 lipoxygenase mediated) pathway whereas levels of 17-HDHA may be reflecting the 17-R 
(P450 or COX-2+ aspirin or statin mediated) pathway. We did not test other DHA derived bioactive lipids such 
as maresins and protectins6 which are likely to have an effect on pain responses (Fig. 1). Although we did not 
measure EPA levels, we did measure an EPA derived resolvin (RvE1) and found no association with heat pain 
thresholds.
One of the benefits of our study is the demonstration that 17-HDHA can be measured both in plasma and 
serum samples in humans. However, we do report large differences between the mean values of 17-HDHA and 
the two D-series resolvins measured in plasma (OA case control study) and serum samples. Although serum and 
heparinized plasma specimens are considered equivalent for some assays, differences in results between sample 
types have been reported for many chemistry analytes30. The higher levels in serum are consistent with what 
is known about resolvin and resolvin precursors (i.e. the presence of platelets generates higher concentration 
of these lipids31. It is important to note that the twin cohort in which we have tested the relationship between 
resolvins were only females. However, the heat pain thresholds data have been used successfully in other studies 
and have been shown to be heritable21. Finally, the OA cohort was only assessed for the standard OA pain instru-
ment (WOMAC) and not for pain thresholds.
In conclusion, we have shown that 17-HDHA is associated with pain in humans, specifically with heat pain 
sensitivity and the intensity of chronic pain, which is unlikely to be due to its being a precursor to other D-series 
resolvins. 17-HDHA is known to be anti-nociceptive in models of OA pain and our novel finding that 17-HDHA 
can modulate pain responses in humans suggest that exogenous administration of 17-HDHA in humans may also 
be analgesic. Further work is needed to understand the anti-nociceptive mechanism of 17-HDHA which will shed 
light on pathways suitable for therapeutic intervention in OA pain.
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